Johnson & Johnson is heading into its third-quarter earnings report with Wall Street expecting another quarter of revenue growth. But rising expectations, pharmaceutical competition, and a major surgical robotics breakthrough could make Tuesday’s results especially important for JNJ investors.
Johnson & Johnson stock is approaching a major earnings test as the healthcare giant prepares to report its third-quarter 2026 financial results on Tuesday, October 13. Wall Street expects the company to generate approximately $25.4 billion in revenue and adjusted earnings of $2.51 per share, putting its pharmaceutical portfolio and medical technology businesses firmly in the spotlight.
The earnings conference call is scheduled for 8:30 a.m. Eastern Time, with CEO Joaquin Duato and Chief Financial Officer Joseph Wolk expected to discuss the results and the company’s outlook.
The announcement arrives at an important moment for Johnson & Johnson (NYSE: JNJ).
After raising its full-year guidance in July, the company is approaching a historic milestone: more than $100 billion in annual revenue for the first time in its 140-year history.
Related articles
Meanwhile, JNJ shares closed at $261.44 on October 9, following a 1.93% gain during the final trading session before earnings week. Despite that rebound, the stock remains below its recent highs, suggesting investors are still weighing the company’s substantial growth opportunities against several unresolved risks.
The biggest question is whether Johnson & Johnson can deliver strong enough results and guidance to justify renewed confidence in its stock.
And with one of the company’s most ambitious medical technology projects reaching a major regulatory milestone, Tuesday’s announcement could reveal much more than another quarter of profits.
Wall Street Expects $25.4 Billion in Revenue, but Earnings Could Disappoint
Analysts are forecasting approximately $25.4 billion in third-quarter revenue, compared with the $24.0 billion Johnson & Johnson reported during the same period in 2025.
That would represent revenue growth of roughly 6%, reflecting continued demand for the company’s pharmaceutical treatments and medical devices.
However, the earnings outlook presents a more complicated picture.
Wall Street expects adjusted earnings of approximately $2.51 per share, below the $2.80 in adjusted EPS reported during the third quarter of 2025. If realized, that would represent a year-over-year decline of approximately 10%.
Key Johnson & Johnson Q3 2026 earnings expectations:
- Expected revenue: $25.4 billion
- Expected adjusted EPS: $2.51
- Q3 2025 revenue: Approximately $24.0 billion
- Q3 2025 adjusted EPS: $2.80
- Latest stock closing price: $261.44
- Earnings date: October 13, 2026
- Earnings conference call: 8:30 a.m. ET
The apparent contrast between rising revenue and declining earnings is important.
Johnson & Johnson operates a complex global healthcare business, where profitability depends on product mix, research spending, litigation-related charges, acquisitions, and other financial factors.
Investors should also distinguish adjusted earnings from reported earnings calculated under generally accepted accounting principles.
If Johnson & Johnson exceeds revenue expectations but fails to deliver the profitability investors anticipate, the market reaction could be mixed.
Conversely, a stronger-than-expected earnings performance accompanied by upbeat guidance could reinforce confidence that the company is successfully managing its transformation.
But the most important benchmark may be the ambitious forecast management issued three months ago.
Johnson & Johnson’s $100 Billion Ambition Raises the Stakes
Johnson & Johnson delivered a strong second quarter in July, reporting revenue of $25.31 billion, an increase of 6.6% from the previous year.
Adjusted earnings reached $2.90 per share, compared with $2.77 a year earlier, representing growth of approximately 4.7%.
Reported net income was approximately $5.53 billion.
The results were sufficiently encouraging for management to raise its full-year outlook.
Johnson & Johnson increased its projected 2026 revenue to approximately $101.1 billion at the midpoint of its guidance range, while raising its adjusted earnings forecast to $11.68 per share.
Those figures represent a significant achievement for a company that has undergone major structural changes, including the separation of its former consumer health business, Kenvue.
Today’s Johnson & Johnson concentrates on two principal divisions: Innovative Medicine and MedTech.
The strategy is designed to generate growth through advanced pharmaceuticals, specialized medical devices, and technologies serving hospitals and healthcare professionals.
But higher guidance also creates higher expectations.
Investors will be looking for confirmation that the company remains on track to exceed $100 billion in annual sales.
A further increase in guidance could become a powerful positive catalyst for Johnson & Johnson stock. Even maintaining the existing outlook would provide reassurance if the third-quarter results demonstrate healthy underlying demand.
A reduction, however, would raise uncomfortable questions about the pace of future growth.
Pharmaceutical Sales Could Decide Whether JNJ Delivers an Earnings Surprise
Johnson & Johnson’s Innovative Medicine division remains the largest contributor to its revenue.
During the second quarter, the business generated approximately $16.38 billion in sales, an increase of 7.8% from the prior year.
The division includes treatments for cancer, immune-mediated diseases, neurological conditions, and other serious health problems.
Its performance is particularly important because pharmaceutical innovation can generate substantial revenue growth when successful treatments receive regulatory approval and gain market share.
Among the company’s major products are DARZALEX, TREMFYA, and CARVYKTI, alongside newer therapies such as CAPLYTA and RYBREVANT-based treatments.
These products offer opportunities for growth, but they also face different competitive and regulatory challenges.
A key issue is whether newer medicines can compensate for pressure on established treatments as patents expire and competing products enter the market.
That transition is especially important following the loss of exclusivity affecting STELARA, previously one of Johnson & Johnson’s most significant pharmaceutical products.
Investors will therefore examine the performance of individual medicines rather than focusing exclusively on total pharmaceutical revenue.
Strong growth from newer oncology and immunology treatments would suggest that Johnson & Johnson’s research investments are producing commercially meaningful results.
But weaker-than-expected sales or disappointing commentary about competition could raise doubts about the company’s longer-term growth assumptions.
The stakes become even higher when considering the company’s ambitions beyond pharmaceuticals.
A Surgical Robotics Breakthrough Could Change Johnson & Johnson’s Future
One of the most interesting developments heading into earnings is Johnson & Johnson’s progress in robotic surgery.
In July, the U.S. Food and Drug Administration granted De Novo marketing authorization for the company’s OTTAVA robotic surgical system.
The technology is designed to support multiple types of general surgery within the upper abdomen, including certain gastrointestinal and bariatric procedures.
The authorization represents an important milestone in Johnson & Johnson’s effort to establish a meaningful presence in the rapidly evolving surgical robotics market.
The company has described OTTAVA as a table-integrated robotic system intended to improve operating room flexibility and surgical workflows.
However, receiving regulatory authorization does not automatically translate into substantial commercial revenue.
Hospitals must evaluate the cost of acquiring and operating new technology, train surgical teams, and determine whether the equipment offers compelling clinical and operational advantages.
Johnson & Johnson will also face competition from established surgical robotics companies, including Intuitive Surgical.
Consequently, investors should be cautious about assuming that OTTAVA will immediately transform the company’s financial performance.
Instead, Tuesday’s conference call could provide important clues about the planned commercial rollout, hospital interest, and expected adoption timeline.
For long-term shareholders, those developments could prove more meaningful than a single quarter of device sales.
MedTech Growth Faces a Bigger Test Than the Headlines Suggest
Johnson & Johnson’s medical technology division generated approximately $8.93 billion in second-quarter revenue, representing growth of 4.5% year over year.
The segment includes products and technologies used in surgery, orthopedics, cardiovascular procedures, and other specialized medical fields.
Its growth prospects are supported by aging populations, advances in medical treatment, and demand for more sophisticated surgical procedures.
However, the business is not immune to pressure.
Hospital budgets, reimbursement policies, competition, and the timing of medical procedures can all influence sales.
Foreign exchange movements also affect reported revenue for a company operating across international markets.
Investors will therefore want to understand whether growth is being driven by genuine increases in product demand or by factors such as acquisitions and currency changes.
Operational sales growth, which excludes currency effects, can offer a more useful indication of the underlying business trend.
A strong MedTech quarter would reinforce Johnson & Johnson’s ability to diversify beyond pharmaceuticals.
More importantly, management’s comments about new technologies, procedure volumes, and hospital spending could help establish whether the division is positioned for faster growth in 2027.
The Talc Litigation Question Has Not Completely Disappeared
Despite its operational strengths, Johnson & Johnson continues to face legal uncertainty related to claims involving its former talc-based products.
In July, the company announced a proposed comprehensive resolution of remaining ovarian talc litigation.
The agreement was designed to address roughly 76,000 claims, subject to conditions including participation by at least 95% of eligible claimants.
Johnson & Johnson has consistently disputed allegations that its talc products caused cancer.
The proposed resolution marked an important development in the company’s efforts to reduce litigation uncertainty, but it did not automatically eliminate every financial and legal risk.
For investors, unresolved litigation can influence valuation because it creates uncertainty about future legal expenses, potential settlement payments, and financial liabilities.
Any update on the proposed agreement could therefore be significant.
A clearer path toward resolution could reduce one of the longstanding concerns surrounding Johnson & Johnson stock.
However, setbacks, additional costs, or uncertainty about participation could remind investors that legal exposure remains part of the company’s financial outlook.
This is particularly relevant for shareholders who view Johnson & Johnson as a relatively defensive investment.
Johnson & Johnson Stock Forecast: Can Earnings Spark Another Rally?
At its October 9 closing price of $261.44, Johnson & Johnson stock was trading below its recent 52-week high of approximately $281.
The stock’s performance reflects optimism about the company’s pharmaceutical pipeline and medical technology ambitions, balanced against concerns about earnings growth, valuation, and legal uncertainty.
Three potential scenarios could determine the market reaction to Tuesday’s results.
Bullish scenario: Strong sales and upgraded guidance.
Johnson & Johnson exceeds revenue and adjusted earnings expectations, delivers healthy pharmaceutical growth, and raises its full-year outlook. Encouraging developments involving OTTAVA and major drug launches could further strengthen investor confidence, potentially supporting a renewed move toward recent share-price highs.
Neutral scenario: Solid growth but few surprises.
Revenue comes in broadly in line with expectations, earnings remain under pressure, and management maintains existing guidance. Investors may remain confident in Johnson & Johnson’s long-term business model while questioning whether near-term growth justifies a higher stock valuation.
Bearish scenario: Profitability or guidance disappoints.
The company misses earnings expectations, reports weaker pharmaceutical growth, or signals slower momentum in MedTech. Any disappointing guidance or unexpected legal expenses could increase selling pressure.
These scenarios are not precise price forecasts. The actual stock reaction will depend on the reported results, management commentary, and broader market conditions.
The most important issue is whether Johnson & Johnson’s future earnings outlook becomes more attractive after Tuesday’s announcement.
Why This Earnings Report Matters for Dividend Investors
Johnson & Johnson has long attracted investors seeking a combination of business stability, dividend income, and long-term capital appreciation.
The company has increased its annual dividend for more than six decades, earning a place among the market’s best-known dividend-growth businesses.
That record reflects a long history of cash generation and capital discipline.
However, dividend reliability does not mean the stock is immune to volatility or that future increases are guaranteed.
Pharmaceutical companies must consistently invest in new medicines to replace revenue lost when patents expire. Medical technology businesses also require substantial spending on research, development, and commercialization.
Investors will therefore be watching free cash flow, profitability, and capital allocation alongside the earnings figures.
A strong cash-generating business provides greater flexibility to fund research, pursue acquisitions, reduce debt, and return capital to shareholders.
For income-focused investors, the sustainability of future cash flow may be more important than whether Johnson & Johnson beats quarterly earnings estimates by a few cents.
The Bottom Line: Johnson & Johnson Must Prove Its Growth Story Is Getting Stronger
Johnson & Johnson enters its October 13 earnings announcement with several important advantages.
Its pharmaceutical portfolio continues to generate billions in revenue, its MedTech business is expanding, and its OTTAVA surgical robotics platform has achieved a significant regulatory milestone.
The company also raised its full-year outlook in July, putting it on a path toward more than $100 billion in annual revenue.
But Wall Street’s expectations are not without challenges.
Analysts anticipate approximately $25.4 billion in third-quarter revenue while forecasting adjusted earnings below the prior-year period. Competition, research spending, litigation uncertainty, and the commercialization of new technologies could all influence future profitability.
Investors should focus on pharmaceutical sales growth, MedTech performance, the commercial outlook for OTTAVA, and any changes to full-year guidance.
Ultimately, a revenue milestone alone may not be enough to drive Johnson & Johnson stock higher. Shareholders will want convincing evidence that the company can turn innovation and expanding sales into sustainable earnings growth.
On October 13, Johnson & Johnson will have an opportunity to show investors whether its next era of healthcare innovation can become its next era of stock-market growth.
Disclaimer
This article is for informational purposes only and does not constitute financial or investment advice. Readers should conduct their own research or consult a qualified financial advisor before making investment decisions. This article was researched and drafted with AI support and should be reviewed, fact-checked, and edited by the editorial team before publication.
